Sutro Biopharma Inc. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance

Reuters

26 Jun

<a href="https://laohu8.com/S/STRO">Sutro Biopharma Inc</a>. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance

Sutro Biopharma Inc. has announced that it received a notice from The NASDAQ Stock Market, LLC on June 20, 2025, indicating that the company is not in compliance with the minimum bid price requirement of $1.00 for continued listing on The NASDAQ Global Market. According to NASDAQ's Listing Rule 5450(a)(1), Sutro Biopharma must raise its closing bid price to at least $1.00 per share for a minimum of ten consecutive business days by December 17, 2025, to regain compliance. The company may be granted an additional 180-day period to comply if it transfers to The Nasdaq Capital Market. Sutro Biopharma is considering measures such as a reverse stock split to meet the requirements before the deadline to prevent delisting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-089978), on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2546252122"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546252122\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2546252122?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546252122","market":"us","top_or_hot":-1,"title":"Sutro Biopharma Inc. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sutro Biopharma Inc. has announced that it received a notice from The NASDAQ Stock Market, LLC on June 20, 2025, indicating that the company is not in compliance with the minimum bid price requirement of $1.00 for continued listing on The NASDAQ Global Market. According to NASDAQ's Listing Rule 5450(a)(1), Sutro Biopharma must raise its closing bid price to at least $1.00 per share for a minimum of ten consecutive business days by December 17, 2025, to regain compliance. The company may be granted an additional 180-day period to comply if it transfers to The Nasdaq Capital Market. Sutro Biopharma is considering measures such as a reverse stock split to meet the requirements before the deadline to prevent delisting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-089978), on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sutro Biopharma Inc. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSutro Biopharma Inc. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-26 04:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sutro Biopharma Inc. has announced that it received a notice from The NASDAQ Stock Market, LLC on June 20, 2025, indicating that the company is not in compliance with the minimum bid price requirement of $1.00 for continued listing on The NASDAQ Global Market. According to NASDAQ's Listing Rule 5450(a)(1), Sutro Biopharma must raise its closing bid price to at least $1.00 per share for a minimum of ten consecutive business days by December 17, 2025, to regain compliance. The company may be granted an additional 180-day period to comply if it transfers to The Nasdaq Capital Market. Sutro Biopharma is considering measures such as a reverse stock split to meet the requirements before the deadline to prevent delisting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-089978), on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STRO","symbol_name":"Sutro Biopharma Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL48lSxC:1","article_id":"2546252122","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546252122","pubTimestamp":1750883463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sutro Biopharma Inc. has announced that it received a notice from The NASDAQ Stock Market, LLC on June 20, 2025, indicating that the company is not in compliance with the minimum bid price requirement of $1.00 for continued listing on The NASDAQ Global Market. According to NASDAQ's Listing Rule 5450, Sutro Biopharma must raise its closing bid price to at least $1.00 per share for a minimum of ten consecutive business days by December 17, 2025, to regain compliance. The company may be granted an additional 180-day period to comply if it transfers to The Nasdaq Capital Market. Sutro Biopharma is considering measures such as a reverse stock split to meet the requirements before the deadline to prevent delisting.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STRO":"Sutro Biopharma Inc","BK4139":"生物科技"},"translate_title":"Sutro Biopharma Inc.因违反最低买入价1美元而可能面临纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STRO":0.9},"content_text":"Sutro Biopharma Inc. Faces Possible NASDAQ Delisting Over $1 Minimum Bid Price Non-Compliance\n    \n\n        Sutro Biopharma Inc. has announced that it received a notice from The NASDAQ Stock Market, LLC on June 20, 2025, indicating that the company is not in compliance with the minimum bid price requirement of $1.00 for continued listing on The NASDAQ Global Market. According to NASDAQ's Listing Rule 5450(a)(1), Sutro Biopharma must raise its closing bid price to at least $1.00 per share for a minimum of ten consecutive business days by December 17, 2025, to regain compliance. The company may be granted an additional 180-day period to comply if it transfers to The Nasdaq Capital Market. Sutro Biopharma is considering measures such as a reverse stock split to meet the requirements before the deadline to prevent delisting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-089978), on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}